These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 32295685)

  • 1. Duration of dual antiplatelet therapy after percutaneous coronary intervention with implantation of second-generation drug-eluting stent: A meta-analysis of randomized controlled trials.
    Liu D; Li YZ; Wu H; Yang J; Yang J; Ding J-; Zhang J; Fan Z-; Yang CJ
    Pharmazie; 2020 Apr; 75(4):113-117. PubMed ID: 32295685
    [No Abstract]   [Full Text] [Related]  

  • 2. Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials.
    Giacoppo D; Matsuda Y; Fovino LN; D'Amico G; Gargiulo G; Byrne RA; Capodanno D; Valgimigli M; Mehran R; Tarantini G
    Eur Heart J; 2021 Jan; 42(4):308-319. PubMed ID: 33284979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shorter (≤6 months) versus longer (≥12 months) duration dual antiplatelet therapy after drug eluting stents: a meta-analysis of randomized clinical trials.
    Pandit A; Giri S; Hakim FA; Fortuin FD
    Catheter Cardiovasc Interv; 2015 Jan; 85(1):34-40. PubMed ID: 24753084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents: A Systematic Review and Network Meta-Analysis.
    Khan SU; Singh M; Valavoor S; Khan MU; Lone AN; Khan MZ; Khan MS; Mani P; Kapadia SR; Michos ED; Stone GW; Kalra A; Bhatt DL
    Circulation; 2020 Oct; 142(15):1425-1436. PubMed ID: 32795096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abbreviated Dual Antiplatelet Therapy Followed by P2Y
    Kumar A; Shariff M; Doshi R; Vaz IP
    Am J Cardiovasc Drugs; 2020 Aug; 20(4):355-361. PubMed ID: 31784888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of antiplatelet regimens after percutaneous coronary intervention using drug eluting stents: A network meta-analysis of randomized controlled trials.
    Garg A; Rout A; Sharma A; Sargsyan D; Beavers T; Tantry U; Gurbel P; Rao SV; Kostis JB; Cohen M
    Prog Cardiovasc Dis; 2020; 63(3):243-248. PubMed ID: 32247786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P2Y12 Inhibitor Monotherapy After a Short Dual Antiplatelet Therapy Versus Standard-Term Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention: A Contemporary Meta-Analysis.
    Ho AC; Egolum U; Parker S; Dimmel J; Hawkins A; Ling H
    Clin Drug Investig; 2020 Sep; 40(9):799-808. PubMed ID: 32661914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    ; Bittl JA; Baber U; Bradley SM; Wijeysundera DN
    Circulation; 2016 Sep; 134(10):e156-78. PubMed ID: 27026019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent: systematic review and network meta-analysis.
    Yin SH; Xu P; Wang B; Lu Y; Wu QY; Zhou ML; Wu JR; Cai JJ; Sun X; Yuan H
    BMJ; 2019 Jun; 365():l2222. PubMed ID: 31253632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-analysis of Dual Antiplatelet Therapy Versus Monotherapy With P2Y12 Inhibitors in Patients After Percutaneous Coronary Intervention.
    Malik AH; Yandrapalli S; Shetty SS; Aronow WS; Cooper HA; Panza JA
    Am J Cardiol; 2020 Jul; 127():25-29. PubMed ID: 32389351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Efficacy and Safety of Duration of Dual Antiplatelet Therapy in Patients with CAD Undergoing Drug-eluting Stent Implantation: A Systematic Review and Network Meta-analysis.
    Guan J; Song W; He P; Fan S; Zhi H; Wang L
    Curr Pharm Des; 2020; 26(44):5739-5745. PubMed ID: 32586248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of P2Y12 inhibitor monotherapy versus dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: systematic review and meta-analysis.
    Wu XT; He RR; Liang SZ; Ye GY; Ding SB
    Minerva Med; 2020 Apr; 111(2):173-180. PubMed ID: 32338843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial.
    Hahn JY; Song YB; Oh JH; Chun WJ; Park YH; Jang WJ; Im ES; Jeong JO; Cho BR; Oh SK; Yun KH; Cho DK; Lee JY; Koh YY; Bae JW; Choi JW; Lee WS; Yoon HJ; Lee SU; Cho JH; Choi WG; Rha SW; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC;
    JAMA; 2019 Jun; 321(24):2428-2437. PubMed ID: 31237645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials.
    Navarese EP; Andreotti F; Schulze V; Kołodziejczak M; Buffon A; Brouwer M; Costa F; Kowalewski M; Parati G; Lip GY; Kelm M; Valgimigli M
    BMJ; 2015 Apr; 350():h1618. PubMed ID: 25883067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term dual antiplatelet therapy (DAPT) followed by P2Y12 monotherapy versus traditional DAPT in patients undergoing percutaneous coronary intervention: meta-analysis and viewpoint.
    Wernly B; Rezar R; Gurbel P; Jung C
    J Thromb Thrombolysis; 2020 Jan; 49(1):173-176. PubMed ID: 31686298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Efficacy and Safety of P2Y12 Inhibitor Monotherapy and Dual Antiplatelet Therapy in Patients with and without Diabetes Mellitus Undergoing Percutaneous Coronary Intervention.
    Feng WH; Chang YC; Lin YH; Chen HL; Chang HM; Chu CS
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35562942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term (1-3 months) versus standard (12 months) dual antiplatelet therapy following new-generation drug-eluting stent implantation: A meta-analysis of randomized controlled trials.
    Xiong P; Zheng C; Fan J; Zhang H; Li C
    Medicine (Baltimore); 2024 May; 103(22):e38071. PubMed ID: 39259115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy After Deployment of a Drug-Eluting Stent: The SHARE Randomized Clinical Trial.
    Min PK; Kang TS; Cho YH; Cheong SS; Kim BK; Kwon SW; Park WJ; Lee JH; Kim W; Lee WS; Yoon YW; Lee BK; Kwon HM; Hong BK;
    JAMA Netw Open; 2024 Mar; 7(3):e240877. PubMed ID: 38451525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of dual antiplatelet therapy after percutaneous coronary drug-eluting stenting: A network meta-analysis.
    Luo L; Wang S; Tang K; Yang X; Wu J; Wang D; Xu L; Feng T; Li D; Ran J; Li D; Zhang L; Zhao D
    Medicine (Baltimore); 2022 Oct; 101(42):e31158. PubMed ID: 36281144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal duration of dual antiplatelet therapy followed by monotherapy in diabetic patients after percutaneous coronary intervention with drug‑eluting stent implantation: a Bayesian network meta-analysis.
    An K; Guo P; Qiu S; Zhu W; Cao W; Shi J; Wang S
    Pol Arch Intern Med; 2021 Sep; 131(9):781-789. PubMed ID: 34132086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.